CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
674.51MUSDvs all stocks (USD)
Revenue (TTM)
117.05MUSDvs all stocks (USD)
Profit Margin
-5.44%vs Biotechnology peers
Beta
4.78xvs all stocks
52-Week Change
-14.79%vs all stocks
Market Capitalization
674.51MUSDvs all stocks (USD)
Enterprise Value
573.30MUSDvs all stocks (USD)
Forward P/E
100.83xvs Biotechnology peers
Price to Sales (TTM)
5.76xvs Biotechnology peers
Price to Book (MRQ)
5.46xvs Biotechnology peers
Enterprise to Revenue
4.90xvs Biotechnology peers
Enterprise to EBITDA
113.01xvs Biotechnology peers
Gross Margin
94.55%vs Biotechnology peers
Profit Margin
-5.44%vs Biotechnology peers
Operating Margin
-30.21%vs Biotechnology peers
Return on Assets (TTM)
1.03%vs Biotechnology peers
Return on Equity (TTM)
-3.08%vs Biotechnology peers
Revenue (TTM)
117.05MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.29USDUpdated Jul 19, 2026Quarterly Revenue Growth
2.10%vs Biotechnology peers
Gross Profit (TTM)
111.30MUSDvs all stocks (USD)
EBITDA (TTM)
11.31MUSDvs all stocks (USD)
Net Income (TTM)
-6.36MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
2.09%vs Biotechnology peers
Operating Cash Flow (TTM)
4.32MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
9.60MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
36.25MUSDFY2025 · Dec 31, 2025Revenue
116.59MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
5.42MUSDFY2025 · Dec 31, 2025Gross Profit
111.17MUSDFY2025 · Dec 31, 2025Operating Income
11.49MUSDvs all stocks (USD)
Pre-tax Income
14.44MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.56MUSDFY2025 · Dec 31, 2025Net Income
9.88MUSDFY2025 · Dec 31, 2025EBIT
11.49MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
11.31MUSDFY2025 · Dec 31, 2025Research & Development
13.70MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
85.98MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.75MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.0600USDFY2025 · Dec 31, 2025EPS (Diluted)
0.0200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
89.34MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
89.34MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
9.88MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-4.85MUSDFY2025 · Dec 31, 2025Operating Cash Flow
2.88MUSDFY2025 · Dec 31, 2025Free Cash Flow
1.72MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
37.07MUSDFY2025 · Dec 31, 2025Income Tax Paid
5.62MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
9.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.52MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-1.11MUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.16MUSDFY2025 · Dec 31, 2025Other Non-cash Items
766.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.95MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
13.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.40MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.16MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-733.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-14.01MUSDFY2025 · Dec 31, 2025Sale of Investments
15.43MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
259.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.49MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
22.02MUSDFY2025 · Dec 31, 2025Shares Outstanding
91.34MSharesUpdated Jul 19, 2026Float Shares
33.93MSharesUpdated Jul 19, 2026Shares Short
1.83MSharesUpdated Jul 19, 2026Short Ratio
14.73daysvs all stocks
Short % of Shares Outstanding
5.19%vs all stocks
% Held by Insiders
86.33%vs all stocks
% Held by Institutions
3.75%vs all stocks
Total Cash (MRQ)
49.81MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.5450USDUpdated Jul 19, 2026Total Debt (MRQ)
823.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0060xvs Biotechnology peers
Current Ratio (MRQ)
4.64xvs Biotechnology peers
Book Value per Share (MRQ)
1.11USDUpdated Jul 19, 2026Total Assets
166.13MUSDvs all stocks (USD)
Total Current Assets
102.37MUSDFY2025 · Dec 31, 2025Total Liabilities
23.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
63.76MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
18.29MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
37.07MUSDFY2025 · Dec 31, 2025Other Short-term Investments
15.36MUSDFY2025 · Dec 31, 2025Accounts Receivable
31.08MUSDFY2025 · Dec 31, 2025Inventory
10.17MUSDFY2025 · Dec 31, 2025Accounts Payable
124.00KUSDFY2025 · Dec 31, 2025Short-term Debt
636.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
111.00KUSDFY2025 · Dec 31, 2025Long-term Debt
303.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.45MUSDFY2025 · Dec 31, 2025Common Stock (Book)
91.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-68.43MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
142.28MUSDvs all stocks (USD)
52-Week Low
5.44USDUpdated Jul 19, 202652-Week High
9.42USDUpdated Jul 19, 202652-Week Change
-14.79%vs all stocks
Beta
4.78xvs all stocks
50-Day MA
6.44USDUpdated Jul 19, 2026200-Day MA
7.40USDUpdated Jul 19, 2026Avg 10-Day Volume
77.35KSharesUpdated Jul 19, 2026Avg 30-Day Volume
108.10KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.0800USDUpdated Jul 19, 2026Other Income / Expense
1.20MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Diagnostic
Earnings Growth With Heavy Accrual Component
It reports a profit, with depreciation heavy in the cash bridge and receivables rising.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.95Profit Margin: -0.05
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Supriya Lifescience Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Lisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Contec Medical Systems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Netflix, Inc.
3 interpretationsEarnings Growth With Heavy Accrual ComponentIndustry-Benchmarked ROA and Margin ElevatedDepreciation-Heavy Reported Profit
Travere Therapeutics Inc.
4 interpretationsEarnings Growth With Heavy Accrual ComponentIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedDepreciation-Heavy Reported Profit
Xeris Biopharma Holdings, Inc.
4 interpretationsEarnings Growth With Heavy Accrual ComponentIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedDepreciation-Heavy Reported Profit